Trial Condition(s):

Carcinoma, Renal Cell, Carcinoma, Renal Cell (Advanced)

A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ® (PONDIAC)

Bayer Identifier:

13102

ClinicalTrials.gov Identifier:

NCT00771147

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Evaluation of the efficacy and safety of Nexavar ® in advanced Renal Cell Carcinoma (RCC) and calculation of related medical costs.

Inclusion Criteria
-  Patients with diagnosis of advanced RCC and decision taken by the investigator to prescribe Nexavar®. The patients should have sufficient
knowledge of French or Dutch to be able to participate in the Study
Exclusion Criteria
-  Exclusion criteria must be read in conjunction with the Belgian product information

Trial Summary

Enrollment Goal
71
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Nexavar (Sorafenib, BAY43-9006)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Belgium

Status
Completed
 

Trial Design